KUX 1151Alternative Names: KUX-0511; KUX-1151
Latest Information Update: 25 Mar 2017
At a glance
- Originator Kissei Pharmaceutical
- Class Antigouts
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Gout; Hyperuricaemia